Dzoanet, as you described it, PTX-200 might be considered as an "ingredient" of Cell-Pryme-M and CellPryme-A.
CellPryme-M is a manufacturing step in the preparation of cell therapies in which PTX-200, as an example of an AKT inhibitor and PH domain inhibitor, may be used in a medium in which cells are cultured.
CellPryme-A is an adjuvant therapy for cellular therapy in which PTX-200 may be used, but likely in combination with a checkpoint inhibitor.
These are new inventions and therefore require new names. I don’t have a problem with that.
If the supposition of PTX playing a crucial role in both CellPryme-M and CellPryme-A is correct, as a shareholder, I’m happy to see the company very cleverly working to derive maximum value from an existing asset.
- Forums
- ASX - By Stock
- Ann: AGM Presentation
Dzoanet, as you described it, PTX-200 might be considered as an...
- There are more pages in this discussion • 8 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add PTX (ASX) to my watchlist
(20min delay)
|
|||||
Last
4.5¢ |
Change
-0.002(4.26%) |
Mkt cap ! $37.85M |
Open | High | Low | Value | Volume |
4.8¢ | 4.8¢ | 4.5¢ | $37.84K | 809.6K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
3 | 264669 | 4.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
4.6¢ | 560 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
3 | 265091 | 0.045 |
2 | 113017 | 0.044 |
5 | 157502 | 0.043 |
3 | 564322 | 0.042 |
3 | 304780 | 0.041 |
Price($) | Vol. | No. |
---|---|---|
0.046 | 560 | 1 |
0.047 | 49532 | 1 |
0.048 | 224589 | 2 |
0.049 | 185000 | 3 |
0.050 | 123539 | 2 |
Last trade - 14.55pm 21/05/2024 (20 minute delay) ? |
|
|||||
Last
4.6¢ |
  |
Change
-0.002 ( 2.13 %) |
|||
Open | High | Low | Volume | ||
4.7¢ | 4.7¢ | 4.6¢ | 428792 | ||
Last updated 14.48pm 21/05/2024 ? |
Featured News
PTX (ASX) Chart |
The Watchlist
ATC
ALTECH BATTERIES LTD
Martin Stein, CFO
Martin Stein
CFO
SPONSORED BY The Market Online